@article{3116366,
    title = "Chronic inflammatory demyelinating polyneuropathy: A 6-year
retrospective clinical study of a hospital-based population",
    author = "Rentzos, M. and Anyfanti, C. and Kaponi, A. and Pandis, D. and Ioannou, and M. and Vassilopoulos, D.",
    journal = "Journal of Clinical Neuroscience",
    year = "2007",
    volume = "14",
    number = "3",
    pages = "229-235",
    publisher = "Elsevier Sci Ltd, Exeter, United Kingdom",
    issn = "0967-5868",
    doi = "10.1016/j.jocn.2006.11.001",
    keywords = "chronic inflammatory demyelinating polyneuropathy (CIDP); clinical
variability; treatment response",
    abstract = "We reviewed the clinical, electrophysiological, laboratory and
neuroimaging features of 25 patients with chronic inflammatory
demyelinating polyneuropathy (CIDP) admitted to Aeginition Hospital from
1996 to 2001. We also investigated the response to several treatment
modalities. The aim was to reveal the clinical spectrum of the disease;
the diagnostic criteria developed by the Ad Hoc Subcommittee of the
American Academy of Neurology (AAN) in 1991 were used. The subjects
consisted of 17 men (68%) and eight women (32%) aged 18-81 years (mean
age: 48.5 years) with CIDP. Eighteen patients (72%) had a symmetric
neuropathy, whereas seven (28%) had an asymmetric neuropathy. Two
patients (8%) had a pure sensory neuropathy. Nine (36%) presented with
cranial nerve involvement and only one (4%) had central nervous system
demyelination. Most patients had a satisfactory response after treatment
with corticosteroids, intravenous immunoglobulins, plasma exchange and
azathioprine. In conclusion, CIDP is a clinically heterogeneous
disorder. It is one of the few serious chronic neuropathies that has a
good (although not permanent) treatment response. (C) 2006 Elsevier Ltd.
All rights reserved."
}